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Purpose: Three VEGF SNPs (−2578) C/A, (+405) G/C and (+936) C/T were investigated in Tunisian exudative AMD
patients in order to determine their association with the disease susceptibility and their influence to intravitreal
bevacizumab therapy response.
Methods: 145 AMD patients and 207 age-matched controls were included. 68 patients were treated with intravitreal
bevacizumab. SNPs genotyping were performed using direct sequencing. The serum VEGF was assayed by ELISA (R&D).
Results: The (+405) CC and (+936) TT genotypes were higher in AMD patients than in controls (p = 5 × 10−6 and
p = 0.021, respectively). The mean plasma levels of VEGF were statistically higher in AMD patients (84.22 pg/ml)
than in controls (15 pg/ml). Three months after bevacizumab treatment, 52 patients (85.6%) were classified as
good responders (GR) and 16 (14.4%) as poor responders (PR). The mean plasmatic-VEGF levels in GR patients was higher
(86.61 ± 80.30 pg/ml) than in PR patients (47.12 ± 45.74 pg/ml) (p = 0.086). The patients with genotype homozygous TT
(+936) would be PR compared to those carrying CT and CC genotypes. Whereas, those with AA (−2578) genotype
would be GR compared with others genotypes (p = 0.014; p = 0.042 respectively).
Conclusions: Our results show that VEGF genetic variants may contribute to the susceptibility to neovascular AMD in
Tunisian patients.
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Age-related macular degeneration (AMD) is a progressive
chronic inflammation that affects the cells of the retinal
pigment epithelium (RPE) and promotes the formation
and deposition of phospholipid material retinal drusen.
This maculopathy progresses to degeneration in two
forms: “wet AMD” and “Dry AMD”. Indeed, most visual
loss occurs in the late stages of the disease due to one
of two processes: choroïdal neovascularization (CNV)
and geographic atrophy [1,2]. Etiological research suggests
that AMD is a complex disease, caused by the interactions
of several genetic and environmental factors. Different* Correspondence: gorgi.yousr@gmail.com
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unless otherwise stated.evidences have supported that in exudative AMD form,
inflammatory lesions are associated with a high expression
and synthesis of growth factors such as vascular endothe-
lial growth factor (VEGF) which is a key regulatory factor
in angiogenesis and vascular permeability in both physio-
logical and pathological states [3]. VEGF expression has
been shown in experimental choroidal neovascularization
and shown to induce CNV growth in animal models [4].
Therefore, it would be involved in the development of
CNV in this disease.
More recently, attention has been focused on the func-
tion of VEGF in light of its role as a therapeutic target and
VEGF-inhibitors have been used in successful therapy of
exudative AMD [5,6]. The most important advance in the
treatment of neovascular AMD is the development of
anti-vascular endothelial growth factor (anti-VEGF) thera-
peutic agents that preserve and improve visual acuity byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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vascular permeability. Thus, VEGF is a potential candidate
for genetically influencing AMD susceptibility, based on
its functional relevance to AMD pathophysiology.
VEGF gene exhibits many single nucleotide polymor-
phisms (SNPs) that might influence qualitatively and/or
quantitatively its expression. Previous studies have shown
that the genetic variations in the VEGF gene influence the
rate of the VEGF protein synthesis [7,8,9]. The human
VEGF-A gene is located on chromosome 6 (6p21.3) and is
organized into eight exons [10]. Several different isoforms
of VEGF are generated by alternate splicing of the VEGF-A
gene [11]. Of these, the VEGF165 isoform (named according
to the number of amino acids), is the most abundant and
corresponds to a 23 kDa polypeptide, constituting a mono-
mer of homodimeric human VEGF-A the role of vascular
endothelial growth factor (VEGF) in inflammatory bowel
disease [12].
In this context, three common VEGF SNPs (C-2578A,
rs699947), (G+ 405C, rs2010963) and (C+ 936 T, rs3025039),
in the promoter, the 5′Untranslate and the 3′Untranslated
regions respectively, were investigated in Tunisian exuda-
tive AMD patients in order to determine their association
with the disease susceptibility, their influence to the level




One hundred and forty five unrelated Tunisian patients
with exudative AMD were collected from the Department
B of Ophthalmology, Hedi Rais Institute of Ophthalmology,
Tunis, Tunisia.
The diagnosis of AMD was established on the basis of
clinical examination, fundus photographs and fluorescein
angiography results. Fundus findings in each eye were
classified based on a standardized set of diagnostic criteria
established by the International Age-Related Maculopathy
Epidemiologic Study [13]. Data obtained from each pa-
tient at the ophthalmology institute included age, gender,
personal/familial history of AMD and risk factors (tobacco
use, arterial hypertension, hypercholesterolemia and car-
diovascular risk). Clinical and epidemiological characteris-
tics of patients are summarized in Table 1.
Exudative AMD patients were classified in two groups.
The first group (G1) composed by 117 patients with active
neovascular form and divided into three subtypes includ-
ing 40 (34,2%) predominantly classic cases without occult
CNV, 53 (45,3%) occult CNV and 24 (20,5%) minimally
classic CNV, according to the guidelines from the inter-
national classification. The second group (G2) included 28
patients with cicatritial lesion form.
According to the standard protocol for anti-VEGF ther-
apy, 68 of G1 patients (58.11%) were treated with 3 initialmonthly intravitreal bevacizumab injections (1.25 mg in
0.05 ml). After this therapy, improving visual acuity (VA),
as a 2-lines gain (a margin of 10 ETDRS lettres) was used
to compare response to treatment. Patients were classified
into:
– Good responders (GR): defined as patients with a gain
of ≥ 10 ETDRS letters and those who demonstrated
stability in visual acuity (a gain or loss of < 5 lettres)
after the 3 bevacizumab injections.
– Poor responders (PR): defined as patients with a loss
of > 10 ETDRS letters in post-therapy.
Controls
Two hundred and seven subjects blood donors older
than 50 years and having undergone a complete ophthal-
mological examination with a normal fundus test, served
as control group.
All patients and controls were fully informed of the
purpose and procedures of the study, and informed consent
was obtained from all patients before they were enrolled in
the study.
Methods
Venous blood of patients and controls was collected in
EDTA tubes. Plasma was frozen at −20°C for determination
of VEGF plasma levels and genomic DNA was extracted
for molecular study using a salting-out procedure [14].
Determination of VEGF plasma levels
Plasmatic VEGF levels of 104 patients included in this
study were measured using the Human VEGF Quantikine
ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA),
according to the manufacturer recommended protocol.
VEGF levels in patient samples were expressed in pg/ml.
The normal mean value of VEGF is 15 ± 4.5 pg/ml. In 68
G1patients, this assay occurred before treatment.
Genotyping of VEGF gene polymorphisms
In the promoter region, the VEGF (−2578) C/A gene
polymorphism was determined using the previously de-
scribed PCR restriction fragment length polymorphism





PCR was carried out in a final volume of 20 μl contain-
ing 100 ng of genomic DNA, 1.5 mM MgCl2, 0.2 mM
dNTP, 10 pmol of each primer and 0.5U of Taq DNA
polymerase (Promega, USA). The PCR product were
digested for 2 hours at 37°C with restriction endonuclease
BglII (SIBENZYME) at a final concentration of 4 units,
fragments were analyzed on 3% agarose gels stained with
Table 1 Clinical and epidemiological characteristics of patients
Patients (n = 145) G1(n = 117) G2 (n = 28)
Sex ratio M/W 99/46 83/34 16/12
Mean age (years ± SD) 73.14 ± 8.06 73.22 ± 8.09 72.71 ± 8.77
Range (years) (52–92) (52–92) (53–89)
Exudative AMD subtypes: n (%)
▪ PC CNV 40(27.59) 40(34.18) -
▪ O CNV 53(36.55) 53(45.29) -
▪ MC CNV 24(16.55) 24(20.51) -
▪ Fibrovascular scarring 28(19,31) - 28(100)
Risk Factors: n (%)
▪ Smoker 91(62.75) 72(61.53) 19(67.85)
▪ Arterial Hypertension 54(37.24) 46(39.31) 8(28.57)
▪ Hypercholestérolemia 28(20.68) 22(18.80) 6(21.42)
▪ Heart risk 27(18.62) 21(17.94) 6(21.42)
▪ History of AMD 9(6.20) 8(6.83) 1(3.57)
▪ Cataract surgery 22(15.17) 17(14.52) 5(17.85)
M: men; W: women; n: number; SD: standard deviation; CNV: choroidal neovascular.
PC: predominantly classic; O: occult; MC: minimally classic.
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C allele was cut into two fragments of 212 and 264 bp.
The VEGF (+405) C/G in the 5′Untranslated region and
(+936) C/T in 3′Untranslated region gene genotyping
were performed by a polymerase chain reaction (PCR)
in a final volume of 20 μl containing 5 pmol of each pri-
mer: 5′-ATTTATTTTTGCTTGCCATT-3′ (forward pri-
mer +405S) and 5′-GTCTGTCTGTCTGTCCGTCA-3′
(reverse primer +405AS); 5′-AAGGAAGAGGAGACTCT
GCGC-3′ (forward primer +936S) and 5′-TATGTGGGT
GGGTGTGTCTACAGG-3′ (reverse primer +936AS) re-
spectively, 50 ng of genomic DNA, 1.5 mM of MgCl2,
0.2 mM dNTP, 10 pmol of each primer and 0.5U of Taq
DNA polymerase (Promega, Madison, WI, USA).
The DNA was denatured at 94°C for 4 minutes, prior
to 30 cycles of amplification. The conditions used for each
cycle were denaturation for 30 seconds at 94°C, annealing
for 30 seconds at 60°C, and extension for 1 minute at 72°C.
The 30 amplification cycles were followed by a final ex-
tension step at 72°C for 5 minutes. The PCR products
were resolved in 2% agarose gels stained with ethidium
bromide. The amplified fragments were then sequenced
in forward direction using the forwards primer in an
ABI PRISM Dye Terminator Cycle Ready Reaction kit
(Applied Biosystems) under recommended conditions.
Sequenced samples were purified using Centri-Sep columns
(Dye EXTm 2.0 Spin Kit, Qiagen) according to manufac-
turer’s instructions, loaded in a PE ABI Prisms 310 Genetic
Analyzer (Perkin Elmer) and analyzed using ABI Prisms
Navigator Software. The (+405) G/C and (+936) C/T al-
leles were observed as different fluorescence peaks in that
position.Statistical analysis
Snellen VA was converted to the logarithm of minimum
angle of resolution (logMAR) VA for the purpose of statis-
tical analysis. Change in VA was calculated as the differ-
ence between VA at baseline and VA at follow-up.
Statistical calculations were performed using SPSS for
Windows 19.0 (SPSS, Chicago, IL, USA). As most data
had a skewed distribution, numbers reported are median
values unless indicated otherwise and non parametric
test methods were used in statistical analyses. Continuous
data were analyzed by Mann–Whitney U-test and categor-
ical data by Fisher’s exact test. Factors that were signifi-
cantly associated with s-VEGF after univariate analyses
were then entered into multiple regression models to de-
termine the independence of potential correlations and to
estimate adjusted ORs (Exp(β)).
Genotype and haplotype analyses were performed with
SNP Stats software. Comparisons between genotypes were
adjusted using the Bonferroni multiple comparison cor-
rection and the reported p-values reflect this correction.
The strength of the association between genotypes or al-
leles in each group was estimated by the calculation of the
odds ratios (OR) and 95% confidence intervals (CI). Values
of p < 0.05 were considered statistically significant.
Results
Genotype and allele frequencies
As shown in Table 2, the genotype and allele frequencies
of the (+405) CC and (+936) TT were significantly
higher in AMD patients than in controls [(OR: 3.86,
95% CI [2.03 - 7.42], p = 5 × 10−6 and OR: 8.89, 95% CI
[1. 05–198.1], p = 0.021 respectively)] and [(OR: 1.79,
Table 2 Distribution of genotype and allele frequencies in patients and in controls; in subgroup and in response to
anti-VEGF
SNPs Patients n = 145 Controls n = 207 G1 n = 117 G2 n = 28 GR n = 52 PR n = 16
n (%) n (%) n (%) n (%) n (%) n (%)
(−2578) CC 19 (13.10) 38 (18.35) 16 (13.67) 3 (10.71) 4 (7.7) 4 (25)
CA 67 (46.21) 88 (42.51) 57 (48.71) 10 (35.71) 24 (46.1) 9 (56.2)
AA 59 (40.69) 81 (39.13) 44 (37.60) 15 (53.57) 24 (46.1)*** 3 (18.8)
C 0.362 0.397 0.380 0.286 0.308 0.531
A 0.638 0.603 0.620 0.714 0.692 0.468
(+405) GG 55 (37.93)* 97 (46,7) 46 (39.31) 9 (32.14) 15 (28.9) 7 (43.8)
GC 51 (35.17) 92 (44.4) 42 (35.89) 9 (32.14) 21 (40.4) 6 (37.5)
CC 39 (26.90) 18 (8.9) 29 (24.78) 10 (35.71) 16 (30.7) 3 (18.8)
G 0.555* 0.688 0.573 0.482 0.490 0.625
C 0.445 0.311 0.427 0.518 0.510 0.375
(+936) CC 101 (69.65) 168 (81.1) 83 (70.94) 18 (64.28) 41 (78.8) 12 (75)
CT 38 (26.21) 38 (18.3) 30 (25.64) 8 (28.57) 11 (21.1) 2 (12.5)
TT 6 (4.14)** 1 (0.6) 6 (3.41) 2 (7.14) 0 2 (12.5)****
C 0.828 0.903 0.838 0.786 0.894 0.810
T 0.172** 0.097 0.179 0.214 0.106 0.190
*Homozygous GG genotype and G allele were significantly higher in AMD patients than in controls [(OR: 3.86, 95%CI [2.03 - 7.42], p = 5 × 10−6 and OR: 1.79, 95%CI
[1.3 - 2.48], p = 2 × 10−4 respectively)].
**Homozygous TT genotype and T allele were significantly higher in AMD patients than in controls [(OR: 8.89, 95%CI [1. 05–198.1], p = 0.021 and OR: 1.95, 95%CI
[1. 22–3.12], p = 0.003 respectively)].
***Homozygous AA (−2578) genotype was statistically associated with good response [(OR: 0.27, 95%CI [0.07- 1.06], p = 0.042)].
****Homozygous TT (+936) genotype was statistically associated with poor response [(OR: 1.61, 95%CI [0.31-8.28], p = 0.014].
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22–3.12], p = 0.003 respectively)]. While, the distribu-
tion of (−2578) C/A genotypes and alleles was similar
among patients and controls.
Otherwise, the distribution of (−2578) C/A, (+405) C/G
and (+936) C/T genotypes and alleles frequencies was simi-
lar in G1 and G2 patients (Table 1). Subtypes of neovascu-
lar AMD did not show statistically significant differences.
Haplotype analysis
Eight different combined haplotypes of these three com-
mun VEGF SNPs were observed Table 3. The cumulative
high risk ACT haplotype was more frequently found inTable 3 Combined haplotypes CA(−2578)/GC(+405)/CT
(+936) frequencies in G1 and G2 patients
Combined haplotypes G1 G2 OR (95% CI) p value
ACC 0.289 0.428 1.00 -
AGC 0.242 0.206 0.59 (0.25-1.38) 0.22
CGC 0.218 0.131 043 (0.17-1.06 0.069
CCC 0.088 0.020 0.13 (0.01-1.12) 0.066
CGT 0.070 0.094 1.06 (0.27-4.23) 0.93
AGT 0.042 0.051 0.73 (0.15-3.48) 0.7
ACT 0.046 0.028 0.48 (0.06-3.85) 0.49
CCT 0.004 0.041 2.67 (0.08-93.16) 0.59patients with the active form of the disease (G1: 4.6%)
compared to those with the scar form (G2: 2.8%), but the
difference was not statistically significant (p = 0.49).
Response to anti-VEGF therapy
Among the 68 G1patients treated with anti-VEGF, at
3 months, 52 patients (85.6%) were classified as good
responders and 16 (14.4%) as poor responders.
VEGF genotyping and response to intravitreal bevacizumab
injections
As summarized in Table 2, no difference was shown
between the distribution of (+405) G/C genotypes and
response to anti-VEGF therapy. However, the patients
with genotype homozygous TT (+936) would be poor
responders compared with those carrying CT and CC
genotypes. Whereas, those with the AA (−2578) genotype
would improve their visual outcome compared with AC
and CC genotypes (p = 0.014; p = 0.042 respectively).
Nevertheless, theses SNPs lose their significance in
analysis of combined haplotypes.
Determination of VEGF plasma levels
Plasmatic VEGF levels in patients were ranged from 10
to 1050 pg/ml. The mean plasma levels of VEGF was
statistically higher in AMD patients (84.22 pg/ml) than
in controls (15 pg/ml), and in active form of AMD
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form (30.60 pg/ml) (p = 0.04 and p = 0.035, respectively)
(Figure 1). However, these results were not confirmed
after multivariate analysis and adjustement for known co-
variates factors (age, gender and risk factors) (Exp (β):
0,95). We did not found any difference in plasmatic VEGF
levels between the different types of CNV (p = 0.23). Add-
itionally, the mean plasma levels of VEGF in GR patients
was higher (86.61 ± 80.30 pg/ml) than in PR patients
(47.12 ± 45.74 pg/ml) with a trend to significance (p =
0.086) (Figure 2).
Association of VEGF polymorphisms with serum VEGF
levels
If the polymorphism (−2578) C/A showed no relationship
with s-VEGF levels of the mutant homozygous genotype
(+405) GG and the wild homozygous genotype (+936) CC
showed a higher s-VEGF levels than the other genotypes
but the differences failed to reach significance.
Additionally, haplotype combinations analysis did not
provide any significant association with s-VEGF levels
variations.
Discussion
The current study showed that (+405) G/C and (+936)
C/T VEGF polymorphisms were statically associated with
exudative AMD in the Tunisian patients corroboratingFigure 1 Distribution of plasma-VEGF levels between the active form
cally higher in G1 (83,39 pg/ml) compared to G2 (30,60 pg/ml) (p=0.035).the large study of Haines et al., who attributed to the
some SNPs of VEGF,VLDLR and LRP6 genes, a role in the
risk of AMD development [15]. These results were in close
agreement with those previously published by Janik-Papis
et al., in a Polish population [16] and by Lin et al., in
Taiwan Chinese population [17]. Inversely, it has been
reported in other studies that the positive association
between VEGF polymorphisms of the gene and suscep-
tibility to the occurrence of AMD could not be con-
firmed in the Rotterdam study and in Anglo-Celtic
subpopulation [18-20]. These controversial results are
due to differences in the size of the study, patients het-
erogeneity, the choice of analyzed SNPs located in the
promoter region and/or in the coding regions and the
methods used for their genotyping. It is now well estab-
lished that genetic susceptibility to complex diseases such
as AMD, is rather due to the cumulative effect of several
predictive alleles identified in the full haplotype informa-
tion [17,18]. Among combined haplotypes observed in this
cohort, the risk ACT variant was more frequently found
in patients with the active form of the disease (G1patients)
compared to those with the scar form (G2 patients), but
the difference was not statistically significant. The small
numbers of subjects in G2 could induce a loss of statistical
power to detect this difference.
The angiogenesis process is highly controlled through
the balance of pro- and anti-angiogenic factors. VEGF isof AMD and the scar form. The mean plasma-VEGF levels was statisti-
Figure 2 A box-plot diagram of plasma-VEGF levels stratified by the treatment response groups. The mean plasma-VEGF levels was higher
in GR (86,61 pg/ml) compared to PR (47,12 pg/ml) (p=0.086).
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in the VEGF gene have been associated with a variation of
protein levels [7,21,22]. The data from this study support
this hypothesis by showing that both in controls and G2
patients compared to the G1 subjects, a significant de-
crease in s-VEGF was observed, confirming once again
that VEGF is the major stimulus for the development and
growth of choroidal neovascularization in the exudative
AMD because wet AMD involves neovascularization, the
best approach for the treatment of CNV appears to be the
use of anti-VEGF drugs. At present, several molecules
have been used in intravitreal therapies approved by Food
and Drug Administration (FDA) and the European Mede-
cines Agency (EMEA).
Among these anti-VEGF agents, several studies report
that the bevacizumab (Avastin*; Genentech Inc) gives the
best results for the treatment of neovascular AMD [23-26].
The effectiveness of such treatments depends on their
molecular weight, the binding affinity of the various iso-
forms of VEGF and their pharmacokinetics lesional prior
retinal barrier. In this study, taking into account of the
availability of bevacizumab exposure in plasma, this
molecule would be more effective in patients with a high
concentration of plasmatic VEGF levels compared to
those with the rate of protein relatively low. Indeed, a
difference in the distribution of plasma levels of VEGF
was found among good responders compared with poor
responders. These results corroborate those of Carneiro
et al., who show that bevacizumab significantly reduced
the plasma levels of VEGF after 28 days after intravitreal
injections in patients with exudative AMD compared
to injections of ranibizumab, with two main potentialdeterminants of their systemic adverse effects including
the blood levels of plasmatic VEGF and the degree of sys-
temic anti-VEGF inhibition.
About the relationship between SNPs of the VEGF gene
studied and response to intravitreal injection of bevacizu-
mab, this study revealed, when each SNP was analyzed
individually, that the patients mutated homozygous AA
(−2578) genotype were rather classified as good responders
whereas those with risk homozygous genotype TT(+936)
belonged to the group of poor responders. Nevertheless,
theses SNPs lose their significance in analysis of combined
haplotypes. In the literature, unanimity is not yet fully
established for the use of these genetic biomarkers to pre-
dict the visual evolution in response to anti-VEGF therapy
in the exudative AMD. Indeed, if in the promoter region
of VEGF gene, the SNP (C-2578A, rs699947) seems to be
also, a predictor of success to bevacizumab treatment in
Japan population [27], our results, concerning the SNP
(C936T, rs3024039) in the 3′Untranslated region, are in
discordance with a Qu Y. in Chinese population and Boltz
A. studies that provide no evidence for an association
between this SNP and the response to bevacizumab
treatment [28,29]. In Korean neovascular AMD cohort,
Un Chul Park et al., do not find statistically significant
effect of VEGF-SNPs (C936T, C-2578A and C-460 T)
on visual outcome after ranibizumab treatment [30]. In
5′Untranslate region, the SNP (G405C, rs2010963), des-
pite the fact that it is associated with susceptibility to
AMD, the response to bevacizumab was independent of
this polymorphisme. This is in agreement with study of
Imai et al. found that VEGF (−2578; rs699947) and PDEF
(+rs113628) were associated with vision changes at 1 month
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VEGF (+405; rs2010963) may not be genetic biomarker to
estimate visual outcomes in response to intravitreal bevaci-
zumab treatment for neovascular AMD [27].
In view of these results, the question is what about the
genetic profile associated with long-term visual outcome?
The follow-up of further study with larger sample sizes
and standard intervals to record the results of visual acuity
should be performed to confirm these results and to an-
swer this question.
In conclusion, this study found that VEGF genetic
variants may contribute to the susceptibility to neovascu-
lar AMD in Tunisian patients and were also associated
with vision changes at 3 months of anti-VEGF therapy.
However, our findings need to be replicated in additional
studies. Further expression studies are needed to investi-
gate the potential pharmacologic role of these variants in
antiangiogenesis AMD therapy at long-term.
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